ReviewFrontiers in cardiovascular medicine2025
Ceramide metabolism and cardiovascular risk factors: insights into therapeutic strategies.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026Review
- Diet-Induced Ceramide Remodeling as a Mechanistic Link to Cardiac Metabolic Dysfunction.Nutrients · 2026Review
- The unified cardiometabolic disease continuum: mechanistic stages of a single pathophysiological process.Frontiers in endocrinology · 2026Review
- Exercise triggers integrated lipid, sphingolipid and purine metabolic alterations in midlife women.Frontiers in physiology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceramides are components of sphingolipid metabolism and have been linked to cardiovascular disease (CVD) risk factors, including hypertension, insulin resistance, dyslipidemia and chronic kidney disease. Ceramide expression has been extensively studied but individual variability, species differences and regulatory mechanisms characterizing underlying relationships remain unclear. The current review analyzes roles of ceramides in the onset and progression of CVD and its risk factors. Diverse ceramide expression profiles are highlighted and recommendations for standardization of ceramide studies given. Ceramides are multifunctional and contribute to organ damage through dysregulated homeostasis during pathological processes. The current work emphasizes the importance of detecting ceramide imbalance and accounting for individual differences as a novel approach to metabolic research. Such a focus may enhance CVD management and give insights into ceramide-related pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.